The Korean Ministry of Food and Drug Safety has approved Amplia Therapeutics' (ASX:ATX) clinical trial to test narmafotinib (AMP945) in combination with gemcitabine and abraxane in advanced pancreatic cancer patients.
Korean regulator approves Amplia Therapeutics' pancreatic cancer trial
December 4, 2023 Australian Biotech
Latest Video
New Stories
-
New partnership promotes buy local for homegrown innovation
May 8, 2025 - - Latest News -
New Zealand to change laws to promote medical conferences
May 8, 2025 - - Latest News -
Australia is about to get a new industry minister
May 8, 2025 - - Latest News -
Internal promotions for new generation of leaders at Astellas
May 7, 2025 - - Latest News -
New study reveals the far-reaching impact of ovarian cancer
May 7, 2025 - - Latest News -
Just the threat of tariffs has secured a quarter of a trillion in investment
May 7, 2025 - - Latest News -
Percheron Therapeutics launches bonus loyalty option offer
May 7, 2025 - - Australian Biotech